Karyopharm Therapeutics Inc. splits its revenue into 2 lines in its filings. The largest line in Q2 of fiscal 2026, the quarter ended Jun 30, 2026 was Product at $30.8 million, 92% of the total.
USD in millions. The percent under a figure is the change from the same quarter a year earlier.
| Line |
TTM
Jun 30, 2026
|
Q2 FY2026
Jun 30, 2026
|
Q1 FY2026
Mar 31, 2026
|
Q4 FY2025
Dec 31, 2025
|
Q3 FY2025
Sep 30, 2025
|
Q2 FY2025
Jun 30, 2025
|
Q1 FY2025
Mar 31, 2025
|
Q4 FY2024
Dec 31, 2024
|
Q3 FY2024
Sep 30, 2024
|
|---|---|---|---|---|---|---|---|---|---|
| Revenue |
147
|
33
|
35
|
34
|
44
|
38
|
30
|
31
|
39
|
| Product |
124
+13.3%
share 84.6%
|
31
+3.7%
share 92.1%
|
29
+38.5%
share 83.2%
|
32
+9.7%
share 94.2%
|
32
+8.5%
share 72.7%
|
30
share 78.3%
|
21
share 70.1%
|
29
share 95.8%
|
30
share 76.1%
|
| License And Other |
23
-18.7%
share 15.4%
|
3
-67.8%
share 7.9%
|
6
-34.1%
share 16.8%
|
2
+54.2%
share 5.8%
|
12
+29.6%
share 27.3%
|
8
share 21.7%
|
9
share 29.9%
|
1
share 4.2%
|
9
share 23.9%
|
How these figures are calculated
Quarterly columns are single-quarter amounts. When a 10-Q reports only a year-to-date total, as cash flow statements do, the quarter is that total minus the previous quarter's year-to-date total. The fourth quarter is the annual report's full year minus the first nine months. A column marked YTD is a year-to-date total, shown when the earlier report needed for the single quarter is missing. USD in millions. Each group is a separate split of total revenue, so the groups are not added together. Share of revenue is that line divided by total revenue. The first column adds the latest year-to-date segment amount to the last fiscal year and subtracts the year-ago year-to-date amount. More on our methodology.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- KPTI (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Newton, MA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1503802
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.